IP Library Granted Patent US 8,815,795
Granted Patent B2
US 8,815,795 · App. 13/684,641 · Granted Aug 26, 2014

Methods for preventing or treating eye diseases using adiponectin

Inventors: Kyung Chul Yoon (Gwangju, KR); Je Moon Woo (Ulsan, KR); Hun Taeg Chung (Ulsan, KR)
Assignee: Industry Foundation of Chonnam National University
A61K38/22A61K9/127A61K38/2264
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,815,795
App. No.
13/684,641
Granted
Aug 26, 2014
Kind
B2
Abstract

A composition for preventing or treating an eye disease includes adiponectin as an active ingredient. Adiponectin as an active ingredient is eventually revealed to show prevention or therapeutic efficacies for eye diseases such as dry eye (syndrome), inflammatory eye disease and side effects due to the use of contact lenses by promoting tear secretion, alleviating ocular surface irregularities, decreasing inflammatory cytokines on the ocular surface and lacrimal gland, and increasing conjunctival goblet cell density. In addition, the composition having eye contact lubrication effects may be used as cleaners or lubricants for preventing non-bacterial inflammation due to wearing contact lenses.

Claims (11)

1. A method for treating a dry eye disease, comprising administering to a subject in need thereof a therapeutically effective amount of a composition comprising an isolated protein comprising the amino acid sequence as set forth in SEQ ID NO:1, as an active ingredient, wherein the administration is performed by a topical administration to ocular surface.

2. The method according to claim 1 , wherein the eye disease is a side effect caused by a use of a contact lens.

3. The method according to claim 1 , wherein the subject is in need of decreasing a level of inflammatory cytokine before the administration, and the composition decreases the level of inflammatory cytokine.

4. The method according to claim 1 , wherein the subject is in need of increasing level of conjunctival goblet cells before the administration, and the composition increases the number of conjunctival goblet cells.

5. The method according to claim 1 , wherein the subject is in need of reducing corneal surface irregularity before the administration, and the composition decreases corneal surface irregularity.

6. The method according to claim 1 , wherein the composition is a formulation selected from the group consisting of solution, suspension, syrup, emulsion, liposome, dust, powder, granule, tablet, sustained-release, eye drop, capsule, contact lens cleaner and contact lens lubricant.

7. The method according to claim 1 , wherein, the composition is encapsulated into liposomes.

8. The method according to claim 1 , wherein the composition is prepared in a sustained-release formulation.

9. A method for lubricating or moisturizing an eye, comprising applying topically to an eye of a subject in need thereof an artificial tear composition comprising an isolated protein comprising the amino acid sequence as set forth in SEQ ID NO: 1 as an active ingredient.

10. The method according to claim 6 , wherein the subject is in need of increasing tear secretion in lacrimal gland, and the active ingredient promotes tear secretion in lacrimal gland.

11. A method for cleaning or lubricating a contact lens, comprising contacting the contact lens with a composition comprising an isolated protein comprising the amino acid sequence as set forth in SEQ ID NO: 1 as an active ingredient.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 26, 2012
From: YOON, KYUNG CHUL; WOO, JE MOON; CHUNG, HUN TAEG
To: INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY
Reel/Frame 029345/0860 →
Priority Claims (1)
KR 10-2012-0084864 · Aug 2, 2012 · national
Continuity (1)
Related Publication 20140037712A1 · Feb 6, 2014